These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 20118547)

  • 1. Pharmacological evaluation of analgesic effects of the cholecystokinin2 receptor antagonist Z-360 in mouse models of formalin- and cancer-induced pain.
    Yoshinaga K; Horii T; Hamano H; Eta R; Ozaki T; Orikawa Y; Yoshii K; Kawabata Y; Hori Y; Seto K; Takei M; Kuraishi Y
    Biol Pharm Bull; 2010; 33(2):244-8. PubMed ID: 20118547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Z-360, a novel therapeutic agent for pancreatic cancer, prevents up-regulation of ephrin B1 gene expression and phosphorylation of NR2B via suppression of interleukin-1 β production in a cancer-induced pain model in mice.
    Orikawa Y; Kato H; Seto K; Kobayashi N; Yoshinaga K; Hamano H; Hori Y; Meyer T; Takei M
    Mol Pain; 2010 Oct; 6():72. PubMed ID: 20979661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Z-360, a novel orally active CCK-2/gastrin receptor antagonist on tumor growth in human pancreatic adenocarcinoma cell lines in vivo and mode of action determinations in vitro.
    Kawasaki D; Emori Y; Eta R; Iino Y; Hamano H; Yoshinaga K; Tanaka T; Takei M; Watson SA
    Cancer Chemother Pharmacol; 2008 Apr; 61(5):883-92. PubMed ID: 17901954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre-clinical evaluation of a new orally-active CCK-2R antagonist, Z-360, in gastrointestinal cancer models.
    Grabowska AM; Morris TM; McKenzie AJ; Kumari R; Hamano H; Emori Y; Yoshinaga K; Watson SA
    Regul Pept; 2008 Feb; 146(1-3):46-57. PubMed ID: 17961733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of intrathecally administered FK480, a cholecystokinin-A receptor antagonist, and YM022, a cholecystokinin-B receptor antagonist, on the formalin test in the rat.
    Yamamoto T; Nozaki-Taguchi N
    Anesth Analg; 1996 Jul; 83(1):107-13. PubMed ID: 8659718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CCK-B receptor antagonist YF476 inhibits pancreatic enzyme secretion at a duodenal level in pigs.
    Evilevitch L; Weström BR; Pierzynowski SG
    Scand J Gastroenterol; 2004 Sep; 39(9):886-90. PubMed ID: 15513388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Z-360, a novel cholecystokinin-2/gastrin receptor antagonist, inhibits gemcitabine-induced expression of the vascular endothelial growth factor gene in human pancreatic cancer cells.
    Kobayashi N; Seto K; Orikawa Y; Hamano H; Yoshinaga K; Takei M
    Biol Pharm Bull; 2010; 33(2):216-22. PubMed ID: 20118543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cholecystokinin octapeptide (CCK-8) antagonizes morphine analgesia in nucleus accumbens of the rat via the CCK-B receptor.
    Pu SF; Zhuang HX; Han JS
    Brain Res; 1994 Sep; 657(1-2):159-64. PubMed ID: 7820614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CCK satiety is differentially mediated by high- and low-affinity CCK receptors in mice and rats.
    Weatherford SC; Laughton WB; Salabarria J; Danho W; Tilley JW; Netterville LA; Schwartz GJ; Moran TH
    Am J Physiol; 1993 Feb; 264(2 Pt 2):R244-9. PubMed ID: 8447480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological profile of T-0632, a novel potent and selective CCKA receptor antagonist, in vivo.
    Taniguchi H; Yazaki N; Yomota E; Shikano T; Endo T; Nagasaki M
    Eur J Pharmacol; 1996 Sep; 312(2):227-33. PubMed ID: 8894600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The type 2 CCK/gastrin receptor antagonist YF476 acutely prevents NSAID-induced gastric ulceration while increasing iNOS expression.
    Webb DL; Rudholm-Feldreich T; Gillberg L; Halim MA; Theodorsson E; Sanger GJ; Campbell CA; Boyce M; Näslund E; Hellström PM
    Naunyn Schmiedebergs Arch Pharmacol; 2013 Jan; 386(1):41-9. PubMed ID: 23179899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antinociceptive effects of RB101, a complete inhibitor of enkephalin-catabolizing enzymes, are enhanced by a cholecystokinin type B receptor antagonist, as revealed by noxiously evoked spinal c-Fos expression in rats.
    Honore P; Buritova J; Fournié-Zaluski MC; Roques BP; Besson JM
    J Pharmacol Exp Ther; 1997 Apr; 281(1):208-17. PubMed ID: 9103499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological profile of FK480, a novel cholecystokinin type-A receptor antagonist: comparison to loxiglumide.
    Ito H; Sogabe H; Nakarai T; Sato Y; Tomoi M; Kadowaki M; Matsuo M; Tokoro K; Yoshida K
    J Pharmacol Exp Ther; 1994 Feb; 268(2):571-5. PubMed ID: 7509389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cholecystokinin is necessary for the expression of morphine conditioned place preference.
    Mitchell JM; Bergren LJ; Chen KS; Fields HL
    Pharmacol Biochem Behav; 2006 Dec; 85(4):787-95. PubMed ID: 17196636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Involvement of cholecystokinin in peripheral nociceptive sensitization during diabetes in rats as revealed by the formalin response.
    Juárez-Rojop IE; Granados-Soto V; Díaz-Zagoya JC; Flores-Murrieta FJ; Torres-López JE
    Pain; 2006 May; 122(1-2):118-25. PubMed ID: 16527403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of evodiamine on gastrointestinal motility in male rats.
    Wu CL; Hung CR; Chang FY; Lin LC; Pau KY; Wang PS
    Eur J Pharmacol; 2002 Dec; 457(2-3):169-76. PubMed ID: 12464363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of a novel cholecystokinin (CCK) receptor antagonist, MK-329, on gallbladder contraction and gastric emptying in humans. Implications for the physiology of CCK.
    Liddle RA; Gertz BJ; Kanayama S; Beccaria L; Coker LD; Turnbull TA; Morita ET
    J Clin Invest; 1989 Oct; 84(4):1220-5. PubMed ID: 2794058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In mononeuropathic rats, the enhancement of morphine antinociception by L-365,260, a selective CCK(B) receptor antagonist, depends on the dose of systemic morphine and stimulus characteristics.
    Idänpään-Heikkilä JJ; Perrot S; Guilbaud G; Kayser V
    Eur J Pharmacol; 1997 May; 325(2-3):155-64. PubMed ID: 9163562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic effect of CART (cocaine- and amphetamine-regulated transcript) peptide and cholecystokinin on food intake regulation in lean mice.
    Maletínská L; Maixnerová J; Matysková R; Haugvicová R; Pirník Z; Kiss A; Zelezná B
    BMC Neurosci; 2008 Oct; 9():101. PubMed ID: 18939974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. (3R)-N-(1-(tert-butylcarbonylmethyl)-2,3-dihydro-2-oxo-5-(2-pyridyl)-1H-1,4-benzodiazepin-3-yl)-N'-(3-(methylamino)phenyl)urea (YF476): a potent and orally active gastrin/CCK-B antagonist.
    Semple G; Ryder H; Rooker DP; Batt AR; Kendrick DA; Szelke M; Ohta M; Satoh M; Nishida A; Akuzawa S; Miyata K
    J Med Chem; 1997 Jan; 40(3):331-41. PubMed ID: 9022799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.